Contact Us
Contact Us

News & Insight

•2025-10-27•

The medical device registration application of Bonvadis® for all indications of wounds has been accepted by Argentina National Administration of Drugs, Foods, and Medical Devices (ANMAT).

In Argentina, there are an estimated 4.3 million adults living with diabetes, the second-highest figure in South America, projected to rise to 5.9 million by 2050. Currently, among diabetic foot ulcer (DFU) patients, the major amputation rate is 8.3% and the mortality rate is 4.49%, highlighting the urgent need for effective treatment options. Argentina’s advanced wound care (AWC) market was valued at approximately USD 96.7 million in 2023 and is expected to reach USD 143.6 million by 2030, with a compound annual growth rate (CAGR) of 5.8%.
Read More
•2025-10-03•

The medical device registration application of Bonvadis® for all indications of wounds has been accepted by COFEPRIS in Mexico.

The advanced wound care market in Mexico and Latin America is experiencing significant growth, driven by an increase in the number of injuries caused by chronic diseases, particularly diabetes. Mexico is the second largest healthcare market in Latin America, with a diabetes prevalence rate of 16.4%, and there is an urgent need for efficient chronic wound care.
Read More
•2025-10-03•

The medical device registration application of Bonvadis® for all indications in wounds has been accepted by ThaiFDA.

According to the International Diabetes Federation (IDF), there are approximately 6.36 million people with diabetes in Thailand. However, due to the lack of effective and cost-effective drugs or medical devices for chronic wounds, the annual burden of wound care is currently estimated to exceed USD 700 million (Int Wound J. 2023 Nov 14;20(10): 3935–3938).
Read More
•2025-07-28•

The medical device registration application of Bonvadis® for all indications in wounds has been accepted by Morocco AMMPS.

Oneness has received notification from the agent today that the medical device registration application of Bonvadis® for all indications has been accepted by AMMPS in Morocco.
Read More
•2025-06-10•

Today, Bonvadis® is 510(k) cleared by the U.S. FDA for full-thickness chronic wounds, marking a significant milestone in international commercialization.

After a three-year, three-phase application process, our product has obtained 510(k) clearances in the U.S for various acute and chronic wound indications.
Read More
•2025-05-21•

Bonvadis® topical cream received medical device marketing authorization approval for all indications in wounds for Australia.

Oneness has received notification from the agent today that the product topical cream received medical device marketing authorization approval for all indications in wounds under ARTG certificate number DV-2025-MC-09357-1 and with permission to be marketed in the Australia.
Read More
•2025-05-09•

The medical device registration application of Bonvadis® for all indications in wounds has been accepted by India CDSCO.

According to Invest India, the country’s medical device market is valued at approximately USD 11 billion and is one of the fastest-growing among emerging markets. With a projected 15% CAGR — 2.5 times the global average — the market is expected to reach USD 50 billion by 2030.
Read More
•2025-04-23•

The medical device registration application of Bonvadis® for all indications in wounds has been accepted by Egypt EDA. 

With a population of approximately 108 million and a diabetic population of approximately 11 million, Egypt's wound care market has great potential.
Read More
•2025-04-16•

The medical device registration application of Bonvadis® for all indications in wounds has been accepted by Australia TGA.

The demand for wound care products in Australia continues to grow steadily. According to the International Diabetes Federation Diabetes Atlas, 11th Edition (2025), the number of people living with diabetes in Australia has reached 1.69 million, reflecting a continuous rise in prevalence.
Read More
1 2